Conference Coverage: ESMO 2024 – Focus on Genitourinary (GU) Malignancies
Impact of recent ESMO data on clinical practice and therapy guidance in GU cancers
September 24, 2024
Faculty Chair
Daniel Petrylak, MD
Yale University, New Haven, CT, USA
FACULTY MEMBERS
Terence Friedlander, MD
University of California, San Francisco, CA, USA
Karim Fizazi, MD, PhD
Gustave Roussy, Villejuif, France
Scott Tagawa, MD, FACP, FASCO
Weill Cornell Medicine, New York, NY, USA
Leonard Gomella, MD, FACS
Sidney Kimmel Cancer Center, Philadelphia, PA, USA
Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Hormonal, Cytotoxic, and Targeted Therapies for Metastatic Castration-Resistant Prostate Cancer
- Radioligand Therapies for Prostate Cancer
- Localized and Hormone-Sensitive Prostate Cancer
- Bladder Cancer Part 1 – NMIBC and MIBC
- Bladder Cancer Part 2 – Metastatic Urothelial Cancer
- Renal Cell Carcinoma
